key: cord-0794543-i873juro
authors: Halfmann, Peter J.; Kuroda, Makoto; Armbrust, Tammy; Accola, Molly; Valdez, Riccardo; Kowalski-Dobson, Theresa; Rehrauer, William; Gordon, Aubree; Kawaoka, Yoshihiro
title: Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model
date: 2022-01-31
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110394
sha: e3d55cf7022941958875b0396c779f466c3140b6
doc_id: 794543
cord_uid: i873juro

The emergence of the SARS-CoV-2 Delta variant (B.1.617.2) raises concerns about potential reduced sensitivity of the virus to antibody neutralization and subsequent vaccine breakthrough infections. Here, we use a live virus neutralization assay with sera from Pfizer- and Moderna-vaccinated individuals to examine neutralizing antibody titers against SARS-CoV-2 and observe a 3.9- and 2.7-fold reduction, respectively, in neutralizing antibody titers against the Delta variant compared with an early isolate bearing only a D614G substitution in its spike protein. We observe similar reduced sensitivity with sera from hamsters that were previously infected with an early isolate of SARS-CoV-2. Despite this reduction in neutralizing antibody titers against the Delta variant, hamsters previously infected (up to 15 months earlier) with an early isolate are protected from infection with the Delta variant, suggesting that the immune response to the first infection is sufficient to provide protection against subsequent infection with the Delta variant.

in the receptor binding domain (L452R and T478K), and a P681R mutation at the S1-S2 furin 65 cleavage site. This latter mutation has been linked to higher viral loads and increased 66 transmission . 

Here, we performed a live virus neutralization assay using serum samples from individuals 74 vaccinated with either BNT162b2 or mRNA-1273. A prototypical virus (SARS-CoV-2/UT-HP095-75 1N/Human/2020/Tokyo; HP095 S-614G) with only the D614G substitution in its spike protein was 76 Delta variant (hCoV-19/USA/WI-UW-5250/2021). We selected 30 serum samples from individuals 78 vaccinated twice with BNT162b2 and 17 serum samples from individuals vaccinated twice with 79 mRNA-1273 (Table S1 ). For both sets of samples, the sera were collected 7-25 days after the 80 second dose. Neutralization titers were higher when the HP095 S-614G virus was used in the 81 assay compared with the Delta variant ( Figure 1A ). With samples from BNT162b2-vaccinated 82 individuals, we observed a 3.9-fold decrease in neutralization titers with the Delta variant 83 compared with the HP095 S-614G reference virus ( Figure 1B) . Similarly, we observed a 2.7-fold 84 decrease in neutralization titers with serum samples collected from individuals vaccinated with 85 mRNA-1273 for the Delta variant when compared against the HP095 S-614G virus ( Figure 1B) . showed a modest reduction in neutralization titers (mean fold change, -6.0) against the Delta 103 variant compared with WA-1 S-614D (Table S2) . 104

At two and half months after the primary infection, the previously infected hamsters were 105 intranasally re-inoculated with 1,000 pfu of WA-1 S-614D (n=4) or the Delta variant (n=4). Age-106 matched (female, 3.5-month-old), naïve control hamsters were also inoculated with 1,000 pfu of 107 WA-1 S-614D (n=4) or the Delta variant (n=4). Three days after inoculation, both viruses 108 replicated to high titers in the nasal turbinates and lungs of the naïve hamsters ( Figure 2A We thank Susan Watson for scientific editing. We also thank the IASO study team for their efforts 176 with the organization and collection of blood samples from individuals after immunization. This from one study and those on the X-axis represent virus titers below the limit of detection (10 209 pfu/g). The bars represent the mean titer for each group There were no significant differences 210 between virus titers in any of the groups shown (p<0.05). 211 

Requests for resources and reagents should be directed to the Lead Contact Author Yoshihiro 225 Kawaoka (yoshihiro.kawaoka@wisc.edu). 226

All unique reagents generated in this study are available from the Lead Contact with completed 228

The datasets supporting the current study are available from the lead contact on request. 231

This paper does not report original code. 232

Any additional information required to reanalyze the data reported in this paper is available from 233 the lead contact upon request. 234

After informed consent was obtained, blood samples were collected from individuals who received 237 Table S1 . for the rest of the study. Nasal washes were collected from the infected hamsters 3 days after 296 infection and from the exposed contact hamsters 2 days after exposure. Tissue samples (lung 297 and nasal turbinate) were collected from the infected hamsters 6 days after infection and from the 298 exposed contact hamsters 4 days after exposure. 299

The sample sizes for the hamster studies were determined from previous studies that 302 demonstrated significant differences among groups. The researchers were not blinded to the 303 group allocations during the experiments. Virus titers from animals are expressed as scatter plots 304 with bars and individual datapoints, obtained by using Graphpad Prism 9. Statistical analyses 305 were performed using two-tailed unpaired Student's t-tests (Graphpad Prism 9). Neutralization 306 titers and fold-changes are displayed as scatter plots with individual datapoints for each serum 307 sample. The geometric mean is shown by the line in each graph and the mean fold changes are 308 shown in parentheses. 309 310   Table S1 . Data on the human serum samples used in the neutralization assays. 311 Table S2 . Neutralization antibody titers and fold-changes obtained with sera from previously 312 infected hamsters. 313 HIGHLIGHTS  Human vaccinee serum neutralizing titers are reduced against SARS-CoV-2 Delta  Similar results are obtained with serum from previously infected hamsters  Prior infection with an early isolate protects hamsters from reinfection with Delta  Prior infection of hamsters prevents Delta transmission to naïve hamsters

As SARS-CoV-2 variants accumulate mutations, there is a risk of ineffective neutralizing antibodies against new variants and potential re-infection. Halfmann et al. report that, in the hamster model, previous infection with an early prototypical SARS-CoV-2 isolate prevents re-infection of the Delta variant and its transmission to naïve hamsters. Table S1 . Data on the human serum samples used in the neutralization assays in Figure 1 . Table S2 . Neutralization antibody titers and fold-changes obtained with sera from previously infected hamsters in Figure 2 .

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough 316 Infections, Associated with Large Public Gatherings

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and 320 transmission in vivo

Syrian hamsters as a small animal model for SARS-CoV-2 infection 323 and countermeasure development

Experimental adaptation of an influenza H5 HA confers respiratory droplet 326 transmission to a reassortant H5 HA/H1N1 virus in ferrets

Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta 329 variant

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent 332 serum

Delta Spike P681R mutation enhances SARS-CoV-2 fitness over Alpha 334 variant

The reproductive number of the Delta variant of SARS-CoV-2 is far higher 336 compared to the ancestral SARS-CoV-2 virus

Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 339 variants

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 342 neutralization

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

WHO: Tracking SARS-CoV-2 Variants

J o u r n a l P r e -p r o o f